Can anti‐A<sub>1</sub> cause hemolysis?

Flegel, Willy A.; Henry, Stephen

doi:10.1111/trf.14996

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 We did not specifically test for anti-A 1 because the clinical relevance of anti-A 1 is controversial and would be overwhelmed by the effect of anti-A. 22,23 Selected units representing a range of anti-A titers were thawed, irradiated, heat-inactivated at 56°C for 120 minutes, and filtered using standard blood filters (Fresenius Kabi). The anti-A titer was repeated after the irradiation, heat inactivation, and filtration (I/HI/F) to ensure anti-A persisted.…”

Section: Donor Plasmamentioning

confidence: 99%

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

et al. 2020

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Most chimeric antigen receptor T (CAR-T) cells and other adoptive T-cell therapies (ACTs) are currently manufactured by ex vivo expansion of patient lymphocytes in culture media supplemented with human plasma from group AB donors. As lymphocytes do not express A or B antigens, the isoagglutinins of non-AB plasmas are unlikely to cause deleterious effects on lymphocytes in culture. STUDY DESIGN AND METHODS: Seeding cultureswith peripheral blood mononuclear cell (PBMNC) concentrates from group A 1 donors and using a CAR-T culture protocol, parallel cultures were performed, each with unique donor plasmas as media supplements (including group O plasmas with high-titer anti-A and group AB plasmas as control). An additional variable, a 3% group A 1 red blood cell (RBC) spike, was added to simulate a RBC-contaminated PBMNC collection. Cultures were monitored by cell count, viability, flow cytometric phenotype, gene expression analysis, and supernatant chemokine analysis. RESULTS:There was no difference in lymphocyte expansion or phenotype when cultured with AB plasma or O plasma with high-titer anti-A. Compared to controls, the presence of contaminating RBCs in lymphocyte culture led to poor lymphocyte expansion and a less desirable phenotype-irrespective of the isoagglutinin titer of the plasma supplement used. CONCLUSIONS:This study suggests that ABO incompatible plasma may be used as a media supplement when culturing cell types that do not express ABO antigens-such as lymphocytes for CAR-T or other ACT. The presence of contaminating RBCs in culture was disadvantageous independent of isoagglutinin titer.A doptive T-cell therapies (ACTs) are being used in numerous applications including cancer treatment, 1-6 prevention of disease relapse following hematopoietic progenitor cell (HPC) transplantation, 7,8 and prevention of viral infections following HPC transplantation. 9-12 T cells used in ACT, whether tumorderived (tumor-infiltrating lymphocytes) or peripherally collected and modified-such as chimeric antigen receptor T (CAR-T) cells or tumor-specific high-affinity T-cell receptorsare traditionally cultured in media supplemented with human AB plasma or serum. [13][14][15] Issues that arise from the use of human plasma include the infectious risk of a donated product, the unpredictable ABBREVIATIONS: ACTs = adoptive T-cell therapies; CAR-T = chimeric antigen receptor T; HLA = human leukocyte antigen; HPC = hematopoietic progenitor cell; I/HI/F = irradiation, heat inactivation, and filtration; IL = interleukin; LOESS = locally estimated scatterplot smoothing; PBMNC = peripheral blood mononuclear cell; PCA = principal component analysis; rIL-2 = recombinant interleukin 2; T CM = central memory; T EM = effector memory; TNCs = total nucleated cells. From the

show abstract

Section: Donor Plasmamentioning

confidence: 99%

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…7 Gone are the days when the only tools available to the investigational immunohematologist were RBCs, polyclonal antibodies, lectins, and natural inhibitory substances. 9 Recombinant peptides and proteins represent the latest addition to our growing toolbox.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of blood group antibodies by soluble substances

et al. 2019

View full text Add to dashboard Cite

The presence of multiple alloantibodies or an antibody to a high-prevalance antigen in a patient sample can pose challenges in antibody identification. The pattern of reactivity seen on an antibody panel may show various strengths of reactivity by different methods of testing or same strength of reactivity at one or more phases of testing. To ensure proper identification, multiple investigative tools may be used. We review one of these methods—inhibition by soluble substances—which has become an expansion of our toolbox within the past 10 years. Alloantibodies can be inhibited using specific soluble substances. These soluble substances occur naturally in various fluids or can be manufactured. When a patient sample contains multiple antibodies, clinically significant or not, inhibition of one may help determine specificities of others. Specific inhibition of a particular antibody will also help to confirm its presence.

show abstract

“…If higher titres correlated with delayed disease progression, plasma with high titre isoagglutinin or monoclonal anti‐A might be a treatment option. Even 25% of blood group A patients, who express an A 2 phenotype, can receive anti‐A 1· 30 …”

mentioning

confidence: 99%

COVID‐19 insights from transfusion medicine

Flegel

2020

Br J Haematol

Self Cite

View full text Add to dashboard Cite

The emergence of CoVID‐19 infection in the first months of 2020 resulted in a massive surge in admissions to hospitals and intensive care units due to the nature of the respiratory pathophysiology. In some countries, health care systems were rapidly overwhelmed, while in others their hospitals coped with the first wave and all patients received the level of care needed, depending upon both the containment measured and the level of development of the heath care systems.

show abstract

Can anti‐A₁ cause hemolysis?

Cited by 4 publications

References 5 publications

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

Inhibition of blood group antibodies by soluble substances

COVID‐19 insights from transfusion medicine

Contact Info

Product

Resources

About

Can anti‐A1 cause hemolysis?

Cited by 4 publications

References 5 publications

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

Inhibition of blood group antibodies by soluble substances

COVID‐19 insights from transfusion medicine

Contact Info

Product

Resources

About

Can anti‐A₁ cause hemolysis?